EL7.AI
StocksMedium•30 July 2026•
1 min read

Glaukos Hits Record High on Q2 Earnings Beat and Raised 2026 Guidance

Key Facts

1Glaukos stock reached a new all-time high following the release of its Q2 2026 financial results.
2The company raised its full-year 2026 revenue guidance based on strong performance.

Amid surging demand for ophthalmic medical solutions, Glaukos shares reached a new all-time high following the release of its Q2 2026 financial results. The rally was sparked by a dual beat on both top and bottom lines, signaling robust operational momentum. According to reports, the company's performance exceeded market expectations, prompting a significant upward revision in its financial outlook.

Following the strong quarterly showing, the company raised its full-year 2026 revenue guidance to a range of $680M-$700M, up from its previous forecast of $620M-$635M. This new guidance sits comfortably above the market consensus of $686.24M, underscoring the company's confidence in its product pipeline and market penetration for the remainder of the fiscal year.

The stock reached a record peak of $183.40 during Thursday's session. Investors are also looking ahead to broader economic catalysts, such as the Dallas Fed Manufacturing Index scheduled for July 27, for further directional cues.